15 July 2019 – Walder Wyss advises Boehringer Ingelheim in the acquisition of Amal Therapeutics SA. Amal is a private Swiss biotechnology company focused on cancer immunotherapy and advancing first in class therapeutic cancer vaccines derived from its technology platform KISIMA. The transaction volume could amount to EUR 325 mio. and is comprised of an upfront payment as well as contingent clinical, development and regulatory milestones plus up to EUR 100 mio. if certain commercial milestones are hit.

The Walder Wyss team comprises Alexander Gutmans (Partner, Corporate/M&A and Venture Capital), Robert von Rosen (Partner, Corporate/M&A and Venture Capital) as well as Sarah Schulthess (Associate, Corporate/M&A).